Incretin hormone has potential to become an antidiabetic therapy

Chiung Mei Weng, Eugene Hsin Yu, Horng-Yih Ou, Ta Jen Wu

Research output: Contribution to journalArticle

Abstract

Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) have the properties of insulinotropic effect. Patients with type 2 diabetes are known as reduced and retarded insulin secretion. Therefore, these incretin effect are reduced in type 2 diabetes. In addition to their insulinotropic effect, they also have some effect on promotion of β cell growth and differentiation, decreasing β cell apoptosis and even decreasing food intake by acting on central nervous system. Due to its glucose dependent insulin secretion effect, the risk of hypoglycemia is low. Therefore, they are potential to develop as antidiabetic treatment. However, there are some difficulties to clinical application of these hormone to lowering blood glucose for type 2 diabetes because of their unfavorable pharmacologic properties. These incretin are rapidly inactivated by dipeptidyl peptidase IV. Recently, different approaches to retard enzyme cleavage by modifying the peptide structures and creating resistance against enzyme inactivation are evaluated.

Original languageEnglish
Pages (from-to)199-207
Number of pages9
JournalJournal of Internal Medicine of Taiwan
Volume15
Issue number5
Publication statusPublished - 2004

Fingerprint

Incretins
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Hormones
Gastric Inhibitory Polypeptide
Insulin
Dipeptidyl Peptidase 4
Glucagon-Like Peptide 1
Enzymes
Hypoglycemia
Blood Glucose
Cell Differentiation
Therapeutics
Central Nervous System
Eating
Apoptosis
Glucose
Peptides
Growth

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Weng, Chiung Mei ; Yu, Eugene Hsin ; Ou, Horng-Yih ; Wu, Ta Jen. / Incretin hormone has potential to become an antidiabetic therapy. In: Journal of Internal Medicine of Taiwan. 2004 ; Vol. 15, No. 5. pp. 199-207.
@article{14cbd649034e425fb786d27aea4a33bc,
title = "Incretin hormone has potential to become an antidiabetic therapy",
abstract = "Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) have the properties of insulinotropic effect. Patients with type 2 diabetes are known as reduced and retarded insulin secretion. Therefore, these incretin effect are reduced in type 2 diabetes. In addition to their insulinotropic effect, they also have some effect on promotion of β cell growth and differentiation, decreasing β cell apoptosis and even decreasing food intake by acting on central nervous system. Due to its glucose dependent insulin secretion effect, the risk of hypoglycemia is low. Therefore, they are potential to develop as antidiabetic treatment. However, there are some difficulties to clinical application of these hormone to lowering blood glucose for type 2 diabetes because of their unfavorable pharmacologic properties. These incretin are rapidly inactivated by dipeptidyl peptidase IV. Recently, different approaches to retard enzyme cleavage by modifying the peptide structures and creating resistance against enzyme inactivation are evaluated.",
author = "Weng, {Chiung Mei} and Yu, {Eugene Hsin} and Horng-Yih Ou and Wu, {Ta Jen}",
year = "2004",
language = "English",
volume = "15",
pages = "199--207",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "5",

}

Incretin hormone has potential to become an antidiabetic therapy. / Weng, Chiung Mei; Yu, Eugene Hsin; Ou, Horng-Yih; Wu, Ta Jen.

In: Journal of Internal Medicine of Taiwan, Vol. 15, No. 5, 2004, p. 199-207.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incretin hormone has potential to become an antidiabetic therapy

AU - Weng, Chiung Mei

AU - Yu, Eugene Hsin

AU - Ou, Horng-Yih

AU - Wu, Ta Jen

PY - 2004

Y1 - 2004

N2 - Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) have the properties of insulinotropic effect. Patients with type 2 diabetes are known as reduced and retarded insulin secretion. Therefore, these incretin effect are reduced in type 2 diabetes. In addition to their insulinotropic effect, they also have some effect on promotion of β cell growth and differentiation, decreasing β cell apoptosis and even decreasing food intake by acting on central nervous system. Due to its glucose dependent insulin secretion effect, the risk of hypoglycemia is low. Therefore, they are potential to develop as antidiabetic treatment. However, there are some difficulties to clinical application of these hormone to lowering blood glucose for type 2 diabetes because of their unfavorable pharmacologic properties. These incretin are rapidly inactivated by dipeptidyl peptidase IV. Recently, different approaches to retard enzyme cleavage by modifying the peptide structures and creating resistance against enzyme inactivation are evaluated.

AB - Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) have the properties of insulinotropic effect. Patients with type 2 diabetes are known as reduced and retarded insulin secretion. Therefore, these incretin effect are reduced in type 2 diabetes. In addition to their insulinotropic effect, they also have some effect on promotion of β cell growth and differentiation, decreasing β cell apoptosis and even decreasing food intake by acting on central nervous system. Due to its glucose dependent insulin secretion effect, the risk of hypoglycemia is low. Therefore, they are potential to develop as antidiabetic treatment. However, there are some difficulties to clinical application of these hormone to lowering blood glucose for type 2 diabetes because of their unfavorable pharmacologic properties. These incretin are rapidly inactivated by dipeptidyl peptidase IV. Recently, different approaches to retard enzyme cleavage by modifying the peptide structures and creating resistance against enzyme inactivation are evaluated.

UR - http://www.scopus.com/inward/record.url?scp=13444282246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444282246&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:13444282246

VL - 15

SP - 199

EP - 207

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 5

ER -